Program
Methotrexate
Also written as “methotrexate”, “Methotrexate (MTX)” and “MTX”.
Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Gout · Arthritis, Psoriatic · Arthritis, Juvenile, led by 24 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 360 open or running | phase 4since Apr 18, 2007 | Oct 21, 2005 | none ahead |
| Bristol-Myers Squibb | 91 open or running | phase 4since Sep 4, 2015 | Jul 19, 2005 | none ahead |
| Pfizer | 80 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| AbbVie | 60 open or running | phase 4since May 25, 2010 | Sep 13, 2005 | none ahead |
| Johnson & Johnson | 60 open or running | phase 3since Dec 11, 2005 | Dec 11, 2005 | none ahead |
| Aldeyra Therapeutics | 31 open or running | phase 3since Oct 21, 2019 | Oct 21, 2019 | Dec 2029phase 3 · NCT07402876 |
| AstraZeneca | 30 open or running | phase 4since Aug 23, 2023 | Sep 16, 2005 | none ahead |
| medac | 31 open or running | phase 3since Jan 11, 2024 | May 14, 2013 | Nov 2026phase 3 · NCT06239311 |
| Merck | 30 open or running | phase 3since Aug 18, 2006 | Aug 18, 2006 | none ahead |
| Halozyme Therapeutics | 20 open or running | phase 2since Jun 4, 2012 | Jun 4, 2012 | none ahead |
| Amneal Pharmaceuticals | 10 open or running | phase 1since Sep 15, 2016 | Sep 15, 2016 | none ahead |
| Azidus Brasil | 10 open or running | phase 2since Apr 15, 2020 | Apr 15, 2020 | none ahead |
| Biocad | 10 open or running | phase 3since Apr 4, 2016 | Apr 4, 2016 | none ahead |
| Biogen | 10 open or running | phase 4since May 27, 2005 | May 27, 2005 | none ahead |
| Celltrion | 10 open or running | phase 1since May 22, 2013 | May 22, 2013 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 4since Dec 4, 2012 | Dec 4, 2012 | none ahead |
| forsight-vision4 | 10 open or running | phase 2since Apr 24, 2014 | Apr 24, 2014 | none ahead |
| gema-biotech-s-a | 10 open or running | phase 3since Apr 21, 2016 | Apr 21, 2016 | none ahead |
| jeffrey-j-crowley-md | 10 open or running | phase 3since Jul 12, 2017 | Jul 12, 2017 | none ahead |
| mediquest-therapeutics | 10 open or running | phase 2since Apr 22, 2008 | Apr 22, 2008 | none ahead |
| nordic-pharma-sas | 10 open or running | phase 3since Sep 16, 2015 | Sep 16, 2015 | none ahead |
| prof-kristian-reich | 10 open or running | phase 3since Jul 26, 2016 | Jul 26, 2016 | none ahead |
| Sanofi | 10 open or running | phase 3since Nov 13, 2014 | Nov 13, 2014 | none ahead |
| xbiotech-inc | 11 open or running | phase 2since Aug 22, 2024 | Aug 22, 2024 | Jan 15, 2027phase 2 · NCT06590090 |
Also a collaborator on its studies: Lakefront Biotherapeutics NV, roche-pharma-ag, Regeneron Pharmaceuticals, integrated-therapeutics-group, accutest-research-laboratories-i-pvt-ltd, ppd-development-lp, UCB, immunex-corporation, basilea-pharmaceutica-international-ltd, Tanabe Pharma, astellas-pharma-us-inc and Eisai.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 47 studies since Aug 18, 2009.
- May 15, 2017Phase 3 study in Arthritis, RheumatoidHoffmann-La Roche · NCT03155347 · 340 enrolled · China
- Jul 12, 2017jeffrey-j-crowley-md's first study: phase 3 study in PsoriasisNew to jeffrey-j-crowley-mdjeffrey-j-crowley-md · NCT03217734 · 56 enrolled · United States
- Oct 21, 2019Aldeyra Therapeutics's first study: phase 3 study in Vitreoretinopathy, ProliferativeNew to Aldeyra TherapeuticsAldeyra Therapeutics · NCT04136366 · 106 enrolled · United States
- Feb 11, 2020Phase 1 study in Healthy VolunteerBristol-Myers Squibb · NCT04268394 · 48 enrolled · United Kingdom
- Apr 15, 2020Azidus Brasil's first study: phase 2 study in COVID-19New to Azidus BrasilAzidus Brasil · NCT04352465 · 42 enrolled · Brazil
- May 28, 2021Phase 3 study in Arthritis, RheumatoidBristol-Myers Squibb · NCT04909801 · 338 enrolled · United States, Argentina, Australia and more
- Mar 28, 2022Phase 2 study in Retinitis PigmentosaAldeyra Therapeutics · NCT05392179 · 8 enrolled · United States
- Jun 30, 2022Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT05445440 · 30 enrolled · United States
- Nov 7, 2022Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT05615012 · 76 enrolled · United States
- Aug 23, 2023Phase 4 study in HypophosphatasiaAstraZeneca · NCT06015750
- Jan 11, 2024Phase 3 study in Moderate to Severe Atopic Dermatitismedac · NCT06239311 · 277 planned · Czechia, France, Italy and more
- Aug 22, 2024xbiotech-inc's first study: phase 2 study in Arthritis, RheumatoidNew to xbiotech-incxbiotech-inc · NCT06590090 · 108 planned
- Jan 29, 2026Phase 3 study in Primary Vitreoretinal LymphomaAldeyra Therapeutics · NCT07402876 · 20 planned · United States
- Nov 16, 2026Primary completion moved from 2026-12 to 2029-12Date moved laterphase 3 · +36 months · NCT07402876
Ahead
- Nov 2026Primary completion: phase 3 study in Moderate to Severe Atopic Dermatitismedac · NCT06239311
- Jan 15, 2027Primary completion: phase 2 study in Arthritis, Rheumatoidxbiotech-inc · NCT06590090
- Dec 2029Primary completion: phase 3 study in Primary Vitreoretinal LymphomaAldeyra Therapeutics · NCT07402876
TargetBeta
“Dihydrofolate reductase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule
Other programs on DHFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 141 |
| pralatrexaterule | Aurobindo Pharma | phase 4 | 19 |
Studies
The newest 60 of 93 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07402876Primary Vitreoretinal Lymphoma · United States | 3 | Recruiting | Aldeyra Therapeutics | Dec 2029 | 20 |
| NCT06590090Arthritis, Rheumatoid | 2 | Not yet recruiting | xbiotech-inc | Jan 15, 2027 | 108 |
| NCT06239311Moderate to Severe Atopic Dermatitis · Czechia, France, Italy and more | 3 | Recruiting | medac | Nov 2026 | 277 |
| NCT06015750Hypophosphatasia | 4 | Withdrawn | AstraZeneca | Mar 13, 2030 | 0 |
| NCT05615012Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Dec 13, 2023 | 76 |
| NCT05445440Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Nov 17, 2022 | 30 |
| NCT05392179Retinitis Pigmentosa · United States | 2 | Completed | Aldeyra Therapeutics | Jun 23, 2023 | 8 |
| NCT04909801Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Jun 14, 2023 | 338 |
| NCT04352465COVID-19 · Brazil | 2 | UNKNOWN | Azidus Brasil | Jun 30, 2020 | 42 |
| NCT04268394Healthy Volunteer · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Jun 2, 2021 | 48 |
| NCT04136366Vitreoretinopathy, Proliferative · United States | 3 | Completed | Aldeyra Therapeutics | Jun 14, 2022 | 106 |
| NCT03217734Psoriasis · United States | 3 | Completed | jeffrey-j-crowley-md | Dec 31, 2018 | 56 |
| NCT03155347Arthritis, Rheumatoid · China | 3 | Completed | Hoffmann-La Roche | Aug 8, 2022 | 340 |
| NCT02940561Psoriasis · India | 1 | UNKNOWN | Amneal Pharmaceuticals | Oct 2016 | 48 |
| NCT02902861Psoriasis Vulgaris · Germany | 3 | Completed | prof-kristian-reich | Sep 2014 | 120 |
| NCT02831855Arthritis, Rheumatoid · United States, Australia, Belgium and more | 4 | Completed | Pfizer | Nov 19, 2018 | 694 |
| NCT02814175Arthritis, Psoriatic · United States, Australia, Brazil and more | 4 | Completed | AbbVie | Sep 23, 2019 | 246 |
| NCT03332719Arthritis, Rheumatoid · Argentina | 3 | Completed | gema-biotech-s-a | Mar 2017 | 168 |
| NCT02744196Arthritis, Rheumatoid | 3 | Completed | Biocad | Feb 2017 | 159 |
| NCT02699710Healthy Volunteer · United Kingdom | 1 | Completed | Hoffmann-La Roche | May 26, 2016 | 50 |
| NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more | 2 | Completed | Hoffmann-La Roche | Aug 2002 | 161 |
| NCT02553018Arthritis, Rheumatoid · France | 3 | Completed | nordic-pharma-sas | Aug 2017 | 278 |
| NCT02557100Arthritis, Rheumatoid · United States, Canada, Mexico | 4 | Completed | Bristol-Myers Squibb | Mar 28, 2019 | 80 |
| NCT02504268Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jan 16, 2017 | 994 |
| NCT02293902Arthritis, Rheumatoid · Japan | 3 | Completed | Sanofi | Oct 2016 | 243 |
| NCT02277444Arthritis, Juvenile · United States, Argentina, Brazil and more | 3 | Completed | Johnson & Johnson | Jul 9, 2018 | 130 |
| NCT02196701Psoriasis | 3 | Completed | AbbVie | Mar 17, 2017 | 46 |
| NCT02187055Rhematoid Arthritis · United States, Argentina, Australia and more | 4 | Completed | Pfizer | Dec 2016 | 1,152 |
| NCT02125266Uveitis, Posterior · United States | 2 | Terminated | forsight-vision4 | Oct 2014 | 7 |
| NCT02097173Psoriasis · United States | 1 | Completed | medac | Oct 2013 | 35 |
| NCT02006706Arthritis, Rheumatoid · Serbia | 3 | Completed | Hoffmann-La Roche | Nov 23, 2007 | 15 |
| NCT01987479Arthritis, Rheumatoid · Netherlands | 3 | Completed | Hoffmann-La Roche | May 26, 2016 | 150 |
| NCT01995201Arthritis, Rheumatoid · Ireland, Portugal, Spain | 3 | Completed | Hoffmann-La Roche | Jul 2015 | 401 |
| NCT01941095Arthritis, Rheumatoid · Greece | 3 | Completed | Hoffmann-La Roche | Jul 10, 2016 | 100 |
| NCT01878318Arthritis, Rheumatoid | 4 | Withdrawn | Hoffmann-La Roche | Jun 2015 | 0 |
| NCT01873443Arthritis, Rheumatoid · Korea, Republic of | 1 | Completed | Celltrion | Oct 2014 | 87 |
| NCT01871961Arthritis, Rheumatoid · United States | 1 | Completed | medac | Feb 2013 | 105 |
| NCT01855789Arthritis, Rheumatoid · United States | 3 | Completed | Hoffmann-La Roche | Oct 14, 2016 | 718 |
| NCT01746680Arthritis, Rheumatoid · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | Jun 2015 | 111 |
| NCT01737944Arthritis, Rheumatoid · United States | 2 | Completed | Halozyme Therapeutics | May 2011 | 38 |
| NCT01661140Arthritis, Rheumatoid · United Kingdom | 4 | Terminated | Hoffmann-La Roche | Feb 2015 | 427 |
| NCT01645280Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more | 2 | Completed | Johnson & Johnson | Dec 2013 | 274 |
| NCT01618968Arthritis, Rheumatoid · United States | 2 | Completed | Halozyme Therapeutics | Aug 2012 | 49 |
| NCT01587989Arthritis, Rheumatoid · Austria | 3 | Completed | Hoffmann-La Roche | Feb 2014 | 77 |
| NCT01399697Arthritis, Rheumatoid · Spain | 4 | Completed | Hoffmann-La Roche | May 2014 | 261 |
| NCT01353859Arthritis, Rheumatoid · Indonesia | 3 | Completed | Hoffmann-La Roche | Jul 2012 | 39 |
| NCT01347983Arthritis, Rheumatoid · Taiwan | 3 | Completed | Hoffmann-La Roche | Mar 2013 | 72 |
| NCT01258712Arthritis, Rheumatoid · Taiwan | 3 | Completed | Hoffmann-La Roche | Oct 2012 | 86 |
| NCT01235507Arthritis, Rheumatoid · Bosnia and Herzegovina | 3 | Completed | Hoffmann-La Roche | Dec 2012 | 71 |
| NCT01185301Arthritis, Rheumatoid · United States, Argentina, Austria and more | 3 | Completed | AbbVie | Sep 2012 | 395 |
| NCT01185288Arthritis, Rheumatoid · United States, Puerto Rico | 4 | Completed | AbbVie | Jan 2013 | 309 |
| NCT01163747Arthritis, Rheumatoid · United States | 4 | Completed | Hoffmann-La Roche | Dec 2011 | 91 |
| NCT01142726Arthritis, Rheumatoid · United States, Australia, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Sep 2013 | 511 |
| NCT01162421Arthritis, Rheumatoid | 4 | Completed | AbbVie | Jul 2015 | 77 |
| NCT01063062Arthritis, Rheumatoid · Egypt | 3 | Completed | Hoffmann-La Roche | Jan 17, 2011 | 107 |
| NCT01034137Arthritis, Rheumatoid · Netherlands | 3 | Completed | Hoffmann-La Roche | Sep 2014 | 317 |
| NCT01007435Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | May 31, 2012 | 1,162 |
| NCT01000610Arthritis, Rheumatoid · Tunisia | 4 | Completed | Hoffmann-La Roche | May 16, 2012 | 18 |
| NCT00973479Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Mar 2011 | 592 |
| NCT00965653Arthritis, Rheumatoid · Canada, New Zealand, Spain | 1 | Completed | Hoffmann-La Roche | 29 |
How it is read
Names in the registry
- “Methotrexate”, 71 entries
- “methotrexate”, 28 entries
- “Methotrexate (MTX)”, 7 entries
- “MTX”, 4 entries
- “methotrexate (MTX)”, 3 entries
Codes read as this program: ADX2191.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 84 studies
- Psoriasis, 10 studies
- Gout, 8 studies
- Arthritis, Psoriatic, 4 studies
- Arthritis, Juvenile, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.